Fatma Karapinar-Çarkit1, Patricia M L A van den Bemt2, Mariam Sadik1, Brigit van Soest3, Wilma Knol4, Florence van Hunsel5, Diana A van Riet-Nales6. 1. Department of Clinical Pharmacy, OLVG hospital, Amsterdam, The Netherlands. 2. Department of Hospital Pharmacy, University Medical Center Groningen, Groningen, The Netherlands. 3. Royal Pharmaceutical Society in the Netherlands (KNMP), The Hague, The Netherlands. 4. Department of Geriatric Medicine and Expertise Centre Pharmacotherapy in Old Persons (EPHOR), University Medical Centre Utrecht, The Netherlands. 5. Netherlands Pharmacovigilance Centre Lareb, 's Hertogenbosch, The Netherlands. 6. Medicines Evaluation Board, Utrecht, The Netherlands.
Abstract
AIMS: Medication safety requires urgent attention in hospital pharmacy. This study evaluated the medication-related problems/errors as reported to the Dutch medication incident registry and disseminated for information to pharmacists. Through analysis by an expert panel we aimed to better understand which problems could have been mitigated by the drug product design. Additionally, the (wider) implications of the problems for current hospital/clinical practice were discussed. METHODS: Items were extracted from the public Portal for Patient Safety. Items were included if relevant for older people and connected with the drug product design and excluded if they should reasonably have been intercepted by compliance to routine controls or well-known professional standards in pharmaceutical care. To explore any underreporting of well-known incidents, it was investigated if different medication-related problems could be observed in a regional hospital practise over a 1-month period. For 6 included items (cases), the implications for hospital/clinical practise were discussed in an expert panel. RESULTS: In total, 307 items were identified in the Portal for Patient Safety; all but 14 were excluded. Six cases were added from daily hospital practice. These 20 cases commonly related to confusing product characteristics, packaging issues such as the lack of a single unit package for an oncolytic product, or incorrect or incomplete user instructions. CONCLUSION: Medication registries provide important opportunities to evaluate real-world medication-related problems. However, underreporting of well-known problems should be considered. The product design can be used as an (additional) risk mitigation measure to support medication safety in hospital practice.
AIMS: Medication safety requires urgent attention in hospital pharmacy. This study evaluated the medication-related problems/errors as reported to the Dutch medication incident registry and disseminated for information to pharmacists. Through analysis by an expert panel we aimed to better understand which problems could have been mitigated by the drug product design. Additionally, the (wider) implications of the problems for current hospital/clinical practice were discussed. METHODS: Items were extracted from the public Portal for Patient Safety. Items were included if relevant for older people and connected with the drug product design and excluded if they should reasonably have been intercepted by compliance to routine controls or well-known professional standards in pharmaceutical care. To explore any underreporting of well-known incidents, it was investigated if different medication-related problems could be observed in a regional hospital practise over a 1-month period. For 6 included items (cases), the implications for hospital/clinical practise were discussed in an expert panel. RESULTS: In total, 307 items were identified in the Portal for Patient Safety; all but 14 were excluded. Six cases were added from daily hospital practice. These 20 cases commonly related to confusing product characteristics, packaging issues such as the lack of a single unit package for an oncolytic product, or incorrect or incomplete user instructions. CONCLUSION: Medication registries provide important opportunities to evaluate real-world medication-related problems. However, underreporting of well-known problems should be considered. The product design can be used as an (additional) risk mitigation measure to support medication safety in hospital practice.
Authors: Hendrik T Ensing; Clementine C M Stuijt; Bart J F van den Bemt; Ad A van Dooren; Fatma Karapinar-Çarkit; Ellen S Koster; Marcel L Bouvy Journal: J Manag Care Spec Pharm Date: 2015-08
Authors: Najla El Morabet; Elien B Uitvlugt; Bart J F van den Bemt; Patricia M L A van den Bemt; Marjo J A Janssen; Fatma Karapinar-Çarkit Journal: J Am Geriatr Soc Date: 2018-02-22 Impact factor: 5.562
Authors: Rose Cairns; Jared A Brown; Ann-Maree Lynch; Jeff Robinson; Carol Wylie; Nicholas A Buckley Journal: Med J Aust Date: 2016-06-06 Impact factor: 7.738
Authors: C A K van der Stelt; A M A Vermeulen Windsant-van den Tweel; A C G Egberts; P M L A van den Bemt; A J Leendertse; W A J J Hermens; R J van Marum; H J Derijks Journal: Drug Saf Date: 2016-01 Impact factor: 5.606
Authors: Fatma Karapinar-Çarkit; Patricia M L A van den Bemt; Mariam Sadik; Brigit van Soest; Wilma Knol; Florence van Hunsel; Diana A van Riet-Nales Journal: Br J Clin Pharmacol Date: 2020-06-24 Impact factor: 4.335
Authors: Diana A van Riet-Nales; Katarina Sundberg; Anthonius de Boer; Blanka Hirschlérova Journal: Br J Clin Pharmacol Date: 2020-10 Impact factor: 4.335